title: Unmet needs in the treatment of allergic asthma: potential role of novel biologic therapies.
abstract: OBJECTIVE
  To provide a review of the current status of the treatment of asthma and introduce new and developing forms of therapy by means of a review of published literature on asthma and publications on new and emerging therapies. Increased public awareness of asthma, improved patient and provider education, implementation of national treatment guidelines, and availability of safe and effective therapies have combined to provide an effective response to the increase in asthma prevalence. However, the number of persons with poorly controlled asthma and asthma-related complications remains unacceptably high. This is particularly true for the relatively small cohort of patients with moderateto- severe asthma that is poorly controlled with inhaled corticosteroids and other standard-of-care medications. Consequently, these patients often experience frequent exacerbations, leading to a disproportionate consumption of asthma health care resources and a poor quality of life. The National Committee on Quality Assurance suggests that the negative impact of asthma can be minimized if health care providers implement aggressive asthma management programs that include patient education and appropriate medications. Newer therapies such as injectable anti-IgE may provide a benefit for many patients.
  
  
  CONCLUSIONS
  Currently available asthma medications have been proven to be generally safe and effective for most asthma patients. However, the subset of patients with difficult-to-treat asthma who experience frequent exacerbations requiring emergency department visits or hospitalizations may benefit from novel therapies designed to target specific mechanisms underlying airway inflammation.
  
  
  CONCLUSIONS
  New therapies may help in the treatment of patients whose asthma is not controlled. These include anti-immunoglobulin E (IgE) antibodies, cytokine modulators, and DNA vaccinations. Future research will determine if these targeted biologic therapies are a cost-effective means to improve the clinical and economic outcomes of asthma management.
authors.affiliation: University of Colorado Health Sciences Center, Colorado Springs, CO 80907, USA. sneezedoc@aol.com
authors.forename: William W
authors.initials: WW
authors.lastname: Storms
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D001249:Asthma / Q000191:economics / Q000453:epidemiology / Q000628:therapy*; D001688:Biological Products / Q000627:therapeutic use*; D016207:Cytokines / Q000037:antagonists & inhibitors; D004636:Emergency Service, Hospital / Q000706:statistics & numerical data; D006297:Health Services Accessibility; D006760:Hospitalization / Q000706:statistics & numerical data; D006801:Humans; D007073:Immunoglobulin E / Q000276:immunology; D008329:Managed Care Programs; D010349:Patient Compliance; D010353:Patient Education as Topic; D017410:Practice Guidelines as Topic; D011788:Quality of Life; D019444:Vaccines, DNA / Q000627:therapeutic use
chemical_list: D000911:Antibodies, Monoclonal; D001688:Biological Products; D016207:Cytokines; D019444:Vaccines, DNA; D007073:Immunoglobulin E